The GTC announced results from the Phase 2B clinical trials of its Wave 1 gene therapy product in 2015. Hyde SC, Gill DR, Higgins CF, Trezise AE, MacVinish LJ, Cuthbert AW, Ratcliff R, Evans MJ, Colledge WH. Cystic fibrosis gene therapy using an adenovirus vector: in vivo safety and efficacy in nasal epithelium. Basic research suggests that CF gene therapy is feasible, but major technological challenges must be addressed before clinical applications are likely to succeed. Wilson JM, Engelhardt JF, Grossman M, Simon RH, Yang Y. Gene therapy of cystic fibrosis lung disease using E1 deleted adenoviruses: a phase I trial. Welsh MJ, Smith AE, Zabner J, Rich DP, Graham SM, Gregory RJ, Pratt BM, Moscicki RA. In vivo gene transfers have been accomplished in CF patients. Gene therapy has shown significant promise not just for people living with cystic fibrosis, but for other genetic diseases. Many tissues are the potential candidates for this approach. Cystic fibrosis (CF) is a rare, heritable disease caused by mutations in the CFTR gene, which provides instructions for making the CFTR protein.This protein normally forms a channel at the membrane of cells for the transport of salts in and out of the cell. 1992 Jan 10; 68 (1):143–155. Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Terence R. Flotte" Barrie J. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. In vivo gene transfers have been accomplished in CF patients. In Vivo Gene Therapy: The direct delivery of the therapeutic gene (DNA) into the target cells of a particular tissue of a patient constitutes in vivo gene therapy (Fig. In this video, Mitch Drumm, PhD, a professor at Case Western Reserve University, answers questions from the CF community about what the future of gene … Cell. Theoretically, cystic fibrosis transmembrane conductance regulator (CFTR) gene replacement during the neonatal period can decrease morbidity and mortality from cystic fibrosis (CF). 1994 Apr; 5 (4):501–519. Theoretically, cystic fibrosis transmembrane conductance regulator (CFTR) gene replacement during the neonatal period can decrease morbidity and mortality from cystic fibrosis (CF). We funded the UK Gene Therapy Consortium (GTC) to develop a gene therapy product with the potential to 'correct' the faulty cystic fibrosis gene in the lungs. 13.6). C a r t e d *Gene Therapy Center University of Florida Gainesville, Florida 326 I0 tTargeted Genetics Corporation Seattle, Washington 98 I0 I In Vivo Gene Therapy with Adeno-Associated Virus Vectors for Cystic Fibrosis 1. Gene replacement therapy represents an interesting new approach for the treatment of cystic fibrosis (CF) lung disease. Hum Gene Ther. Gene delivery can be carried out by viral or non- viral vector systems. These include liver, muscle, skin, spleen, lung, brain and blood cells.